Savara (NASDAQ:SVRA) Stock Price Up 4.1% – Here’s Why

by · The Cerbat Gem

Savara Inc (NASDAQ:SVRA – Get Free Report)’s share price rose 4.1% during trading on Tuesday . The company traded as high as $3.05 and last traded at $3.02. Approximately 101,330 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 1,328,423 shares. The stock had previously closed at $2.90.

Analyst Ratings Changes

SVRA has been the subject of a number of recent analyst reports. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company initiated coverage on shares of Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Savara in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.83.

Read Our Latest Stock Analysis on Savara

Savara Stock Up 2.1 %

The stock has a market cap of $510.99 million, a P/E ratio of -6.88 and a beta of 0.52. The firm has a 50 day simple moving average of $2.72 and a two-hundred day simple moving average of $3.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.

Savara (NASDAQ:SVRA – Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $0.27 million during the quarter. Equities research analysts predict that Savara Inc will post -0.45 earnings per share for the current year.

Institutional Investors Weigh In On Savara

A number of large investors have recently made changes to their positions in SVRA. The Manufacturers Life Insurance Company lifted its position in shares of Savara by 9.0% in the third quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock worth $191,000 after purchasing an additional 3,706 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Savara by 258.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after buying an additional 18,534 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Savara by 5.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock valued at $533,000 after acquiring an additional 6,141 shares during the last quarter. State Street Corp increased its stake in shares of Savara by 15.7% during the 3rd quarter. State Street Corp now owns 4,138,276 shares of the company’s stock worth $17,546,000 after purchasing an additional 560,242 shares during the last quarter. Finally, Barclays PLC increased its position in Savara by 217.5% during the third quarter. Barclays PLC now owns 231,005 shares of the company’s stock worth $979,000 after buying an additional 158,244 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

(Get Free Report)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Featured Articles